See more : Mangalam Organics Limited (MANORG.NS) Income Statement Analysis – Financial Results
Complete financial analysis of KalVista Pharmaceuticals, Inc. (KALV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KalVista Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- North American Construction Group Ltd. (NOA) Income Statement Analysis – Financial Results
- Sealand Securities Co., Ltd. (000750.SZ) Income Statement Analysis – Financial Results
- Henan Dayou Energy Co., Ltd (600403.SS) Income Statement Analysis – Financial Results
- Ally Leasehold Real Estate Investment Trust (ALLY.BK) Income Statement Analysis – Financial Results
- Neovasc Inc. (NVCN) Income Statement Analysis – Financial Results
KalVista Pharmaceuticals, Inc. (KALV)
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 12.69M | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M | 415.00K | 1.54M |
| Cost of Revenue | 86.17M | 802.00K | 743.00K | 651.00K | 40.19K | 35.02K | 18.24K | 12.67K | 14.66K | 8.29K | 0.00 | 0.00 |
| Gross Profit | -86.17M | -802.00K | -743.00K | 12.04M | 12.65M | 16.09M | 8.38M | 1.49M | 2.12M | 1.80M | 415.00K | 1.54M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 94.87% | 99.68% | 99.78% | 99.78% | 99.16% | 99.31% | 99.54% | 100.00% | 100.00% |
| Research & Development | 86.17M | 80.28M | 70.17M | 41.29M | 40.19M | 35.02M | 18.24M | 12.67M | 14.66M | 8.29M | 4.23M | 1.96M |
| General & Administrative | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Other Expenses | -86.17M | 15.64M | 14.72M | 9.93M | 9.83M | 7.68M | 4.39M | 2.33M | 2.03M | 844.00K | -59.00K | 35.00K |
| Operating Expenses | 54.28M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Cost & Expenses | 140.45M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Interest Income | 0.00 | 2.23M | 1.09M | 903.00K | 1.83M | 1.40M | 82.00K | 36.00K | 50.00K | 19.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 405.00K | 256.00K |
| Depreciation & Amortization | 816.00K | 802.00K | 743.00K | 651.00K | 525.00K | 378.00K | 180.00K | 40.00K | 133.00K | 38.00K | 27.00K | 38.00K |
| EBITDA | -134.28M | -92.11M | -81.60M | -45.59M | -40.02M | -29.44M | -18.53M | -22.30M | -15.15M | -8.05M | -5.25M | -1.76M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -458.89% | -312.48% | -182.87% | -201.94% | -1,573.80% | -788.05% | -446.29% | -1,264.10% | -114.37% |
| Operating Income | -140.45M | -110.87M | -96.61M | -57.92M | -40.53M | -29.82M | -18.71M | -22.34M | -15.18M | -8.09M | -5.22M | -1.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -456.45% | -319.41% | -184.91% | -222.84% | -1,485.31% | -711.72% | -448.39% | -1,256.87% | -119.18% |
| Total Other Income/Expenses | 5.35M | 17.96M | 14.27M | 11.68M | 11.29M | 9.13M | 2.90M | 3.74M | 3.75M | 863.00K | -462.00K | -220.00K |
| Income Before Tax | -135.10M | -92.91M | -82.34M | -46.24M | -29.24M | -20.69M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -364.41% | -230.42% | -128.31% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| Income Tax Expense | -8.45M | -18.05M | -13.83M | -1.75M | -124.00K | 124.00K | -1.33M | -5.11M | -5.41M | -863.00K | 462.00K | 220.00K |
| Net Income | -126.64M | -74.85M | -68.51M | -44.49M | -29.12M | -20.82M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -350.62% | -229.44% | -129.08% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| EPS | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| EPS Diluted | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| Weighted Avg Shares Out | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
| Weighted Avg Shares Out (Dil) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
KalVista (KALV) Surges 15% on Update From Angioedema Study
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the fiscal...
KalVista Pharmaceuticals to Present Data at the 2023 Meeting of the European Academy of Allergy and Clinical Immunology (EAACI)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 European...
KalVista Pharmaceuticals to Present at Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Jefferies Global Healthcare Conference...
KalVista Pharmaceuticals to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day Virtual Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the...
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today that it made two oral presentations and one poster presentation...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on May...
KalVista Pharmaceuticals to Present Data at the 13th C1-inhibitor Deficiency & Angioedema Workshop
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 13th C1-inhibitor...
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the...
Source: https://incomestatements.info
Category: Stock Reports